The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
Open accessAbstract
BACKGROUND: Plasma triglyceride levels are heritable and are correlated with the risk of coronary heart disease. Sequencing of the protein-coding regions of the human genome (the exome) has the potential to identify rare mutations that have a large effect on phenotype. METHODS: We sequenced the protein-coding regions of 18,666 genes in each of 3734 participants of European or African ancestry in the Exome Sequencing Project. We conducted tests to determine whether rare mutations in coding sequence, individually or in aggregate within a gene, were associated with plasma triglyceride levels. For mutations associated with triglyceride levels, we subsequently evaluated their association with the risk of coronary heart disease in 110,970 persons. RESULTS: An aggregate of rare mutations in the gene encoding apolipoprotein C3 (APOC3) was associated with lower plasma triglyceride levels. Among the four mutations that drove this result, three were loss-of-function mutations: a nonsense mutation (R19X) and two splice-site mutations (IVS2+1G→A and IVS3+1G→T). The fourth was a missense mutation (A43T). Approximately 1 in 150 persons in the study was a heterozygous carrier of at least one of these four mutations. Triglyceride levels in the carriers were 39% lower than levels in noncarriers (P<1×10(-20)), and circulating levels of APOC3 in carriers were 46% lower than levels in noncarriers (P=8×10(-10)). The risk of coronary heart disease among 498 carriers of any rare APOC3 mutation was 40% lower than the risk among 110,472 noncarriers (odds ratio, 0.60; 95% confidence interval, 0.47 to 0.75; P=4×10(-6)). CONCLUSIONS: Rare mutations that disrupt APOC3 function were associated with lower levels of plasma triglycerides and APOC3. Carriers of these mutations were found to have a reduced risk of coronary heart disease. (Funded by the National Heart, Lung, and Blood Institute and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Observational cohorts demonstrate that higher TG and remnant cholesterol predict cardiovascular events independently of LDL-C, while Mendelian randomization analyses confirm a causal relationship between lifelong TRL elevation and ASCVD.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [60]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrary, loss-of-function mutations of the ApoC-III are associated with a lower risk of CVD [170–172].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [172]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apolipoprotein C-III is a central regulator of triglyceride metabolism that limits the clearance of triglyceride-rich lipoproteins through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoprotein remnants. 6-8”
From Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, loss-of-function mutations in APOC3, which encodes apolipoprotein C-III, result in significantly lower plasma TG levels and confer a 40–50% lower risk of ischemic cardiovascular events [25].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss-of-function variants in APOC3 confer protection against coronary artery disease, independent of LDL cholesterol levels [60, 112]”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [60]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Individuals with loss-of-function mutations in APOC-III exhibit significantly reduced levels of triglycerides and remnant cholesterol, along with a nearly 40% reduction in ASCVD risk [32, 33].”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [32]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Individuals with genetic loss-of-function mutations in the APOC3 gene exhibit markedly lower TG levels and reduced incidence of CAD, highlighting apoC-III as a compelling therapeutic target for HTG and associated complications [25, 29, 43].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, with genetic studies supporting the role of several novel therapeutic targets (eg, apo C-III and ANGPTL3) in atherosclerosis, ongoing clinical trials using RNA interference therapy (antisense oligonucleotides and small interfering RNAs) have the potential to further inform our understanding of the triglyceride-based atherosclerotic pathways (120,121).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [120]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Two large randomized controlled trials (RCTs) evaluating the efficacy of extended-release niacin vs placebo on background statin therapy in individuals with established ASCVD did not demonstrate a reduction in vascular events”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
In the citing paper
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
In the citing paper
“and is a genetically validated target to reduce ASCVD risk.8–10,64–66”
From Clinical review on triglycerides (2020) · cites this paper as [64]
In the citing paper
“ApoCIII has been identified as a potentially important new risk factor. 104-106”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [106]
In the citing paper
“Furthermore, loss of function mutations are associated with low TGs as well as with reduced risk for CVD. 106,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [106]
In the citing paper
“Furthermore, loss of function mutations are associated with low TGs as well as with reduced risk for CVD.106,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [106]
In the citing paper
“defects in genes controlling TG metabolism, including APOC3, ANGPTL3 and ANGPTL4 that have been linked to reduced TG and are associated with reduced coronary calcification25 or reduced CVD risk.26-30”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,457
Multi-Ethnic Study of Atherosclerosis: Objectives and Design
Bild, D. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf113 · Cited by 3,942
The Cardiovascular Health Study: design and rationale.
Fried, L. P., Borhani, N. O., Enright, P., Furberg, C. D., Gardin, J. M., Kronmal, R. A., Kuller, L. H., Manolio, T. A., Mittelmark, M. B., Newman, A., et al. (1991) · Annals of Epidemiology · doi:10.1016/1047-2797(91)90005-w · Cited by 3,652
Robust relationship inference in genome-wide association studies
Manichaikul, A., Mychaleckyj, J. C., Rich, S. S., Daly, K., Sale, M., & Chen, W.-M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq559 · Cited by 3,541
THE ATHEROSCLEROSIS RISK IN COMMUNIT (ARIC) STUDY: DESIGN AND OBJECTIVES
THE ARIC INVESTIGATORS (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115184 · Cited by 3,498
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Flagged first, then by citations
1 of the 66 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Taylor HA, 2005, Ethn Dis, 15, S4
Cited by
Sorted by citations
Items 701–800 of 1,001
Rout, M., Lerner, M. R., Blackett, P. R., Peyton, M. D., Stavrakis, S., Sidorov, E. V., & Sanghera, D. K. (2022) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100128 · Cited by 8
Approach to patients with hypertriglyceridemia
Chait, A., & Feingold, K. R. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101659 · Cited by 8
Young, K. L., Fisher, V. A., Deng, X., Brody, J. A., Graff, M., Lim, E., Lin, B. M., Xu, H., Amin, N., An, P., et al. (2022) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2022.100163 · Cited by 8
HPS2-THRIVE, AIM-HIGH and dal-OUTCOMES: HDL-cholesterol under attack
Hassan, M. S. (2014) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2014.37 · Cited by 9
Sex‐Specific Parental Effects on Offspring Lipid Levels
Predazzi, I. M., Sobota, R. S., Sanna, S., Bush, W. S., Bartlett, J., Lilley, J. S., Linton, M. F., Schlessinger, D., Cucca, F., Fazio, S., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.001951 · Cited by 8
Dancer, M. S., Caussy, C., Filippo, M. D., Moulin, P., Marçais, C., & Charrière, S. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.10.024 · Cited by 9
Jo, G., Kwak, S., Kim, J. Y., Lim, H., & Shin, M. (2018) · Nutrients · doi:10.3390/nu10111595 · Cited by 9
Malalla, Z. H. A., Al‐Serri, A., Alaskar, H., Al-Kandari, W. Y., & Al‐Bustan, S. A. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1165-6 · Cited by 8
Pedro‐Botet, J., Ascaso, J. F., Blasco, M., Brea, Á., Rodríguez, Á. D., Hernández‐Mijares, A., Pintó, X., & Millán, J. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.12.003 · Cited by 14
Experimental Biology for the Identification of Causal Pathways in Atherosclerosis
Guo, Y., Garcia-Barrio, M. T., Wang, L., & Chen, Y. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6644-7 · Cited by 8
Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease
Kosmas, C. E., Sourlas, A., Silverio, D., Montan, P. D., & Guzman, E. (2019) · World Journal of Cardiology · doi:10.4330/wjc.v11.i11.256 · Cited by 8
Gene-based therapies for steatotic liver disease
Iakovleva, V., & de Jong, Y. P. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.024 · Cited by 7
Yang, X., Alexander, V. J., Xia, S., & Tsimikas, S. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120462 · Cited by 7
Bazarbashi, N., & Miller, M. J. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.11.006 · Cited by 7
Treating Cardiovascular Disease with Liver Genome Engineering
Hurley, A. E., & Lagor, W. R. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00986-z · Cited by 7
Increasing the complexity of lipoprotein characterization for cardiovascular risk in type 2 diabetes
Guardiola, M., Rehues, P., Amigó, N., Arrieta, F., Botana, M., Gimeno-Orna, J. A., Girona, J., Martínez‐Montoro, J. I., Ortega, E., Pérez, A., et al. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14214 · Cited by 7
Xiao, Q., Wang, L., Wang, J., Wang, M., Wang, D. W., & Ding, H. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102011 · Cited by 8
Balling, M., Afzal, S., Varbo, A., Nordestgaard, B. G., & Langsted, A. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvae217 · Cited by 10
Schwartz, G. G., Szarek, M. J., Reijnders, E., Jukema, J. W., Bhatt, D. L., Bittner, V., Fazio, S., Garon, G., Goodman, S. G., Harrington, R. A., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf067 · Cited by 7
Packard, C. J., Taskinen, M., Björnson, E., Matikainen, N., Söderlund, S., Andersson, L. K., Adiels, M., & Borén, J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119166 · Cited by 7
Jeff, J. M., Peloso, G. M., & Do, R. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000277 · Cited by 7
Clarifying complex inheritance: apolipoprotein C3 and atherosclerosis
Galton, D. J. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000425 · Cited by 7
Assessing Rare Variation in Complex Traits
Kuchenbaecker, K. B., & Appel, E. V. R. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7868-7_5 · Cited by 6
Hallén, J., & Sreeharan, N. (2018) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvy029 · Cited by 7
Young, E. P., & Stitziel, N. O. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-041717-085853 · Cited by 7
Reyes‐Soffer, G. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000619 · Cited by 13
Ding, Y., Shi, Y., Wang, L., Li, G., Osman, R. A., Sun, J., Qian, L., Zheng, G., & Zhang, G. (2021) · European Journal of Neurology · doi:10.1111/ene.15213 · Cited by 7
Managing of dyslipidaemia characterized by accumulation of triglyceride-rich lipoproteins
Visser, J., van Zwol, W., & Kuivenhoven, J. A. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00979-y · Cited by 7
Targeting triglycerides to lower residual cardiovascular risk
Bubb, K. J., Nelson, A. J., & Nicholls, S. J. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2058489 · Cited by 8
Non-coding RNA-Associated Therapeutic Strategies in Atherosclerosis
Tang, Y., Li, H., & Chen, C. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.889743 · Cited by 8
Sakai, R., Sekimoto, T., Koba, S., Mori, H., Matsukawa, N., Arai, T., Yokota, Y., Sato, S., Tanaka, H., Masaki, R., et al. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.01.004 · Cited by 7
Unraveling New Therapeutic Targets of Coronary Artery Disease by Genetic Approaches
Lee, S. E., & Kim, H.-S. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-0985 · Cited by 7
Cardiovascular risk reduction: the future of cholesterol lowering drugs
Malham, S. B., & Goldberg, A. C. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.01.007 · Cited by 8
Using human genetics to discover new therapeutic targets for plasma lipids
Cohen, J. C. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12521 · Cited by 7
Mechanistic insights from combining genomics with metabolomics
Drenos, F. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000393 · Cited by 7
Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects
Filippatos, T. D., Liontos, A., Christopoulou, E. C., & Elisaf, M. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180209112351 · Cited by 7
Abbey, D., Conlon, D., Rainville, C., Elwyn, S., Quiroz‐Figueroa, K., Billheimer, J. T., Schultz, D., Hand, N. J., Cherry, S. R., & Rader, D. J. (2021) · Clinical and Translational Science · doi:10.1111/cts.12988 · Cited by 7
Dedousis, N. L., Teng, L., Kanshana, J. S., & Kohan, A. B. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100284 · Cited by 7
Peng, X., Lian, Z., O’Brien, V., Xiao, J., Litchfield, B., Perrard, X. D., Lu, X., Ni, J., Mukherjee, A., Simmons, T., et al. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100763 · Cited by 7
Björnson, E., Packard, C. J., Adiels, M., Leeper, N. J., Hellawell, J. L., Gummesson, A., Nissen, S. E., & Borén, J. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf657 · Cited by 6
Genetic Assessment and Clinical Correlates in Severe Hypertriglyceridemia: A Systematic Review
Luca, C. D., Ciciola, P., D’Errico, G., Taranto, M. D. D., Fortunato, G., Gross, C., Garn, J., Iannuzzo, G., Minno, M. N. D. D., & Calcaterra, I. L. (2025) · Genes · doi:10.3390/genes16111377 · Cited by 7
Björnson, E., Adiels, M., Taskinen, M., Packard, C. J., & Borén, J. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01399-y · Cited by 8
Silencing ApoC3 alleviates LPS-induced acute lung injury by inhibiting TLR signaling pathway
Qi, Y., Chen, C., Li, X., Liu, Y., Qi, H., Xue, Y., & Yang, F. (2023) · Immunologic Research · doi:10.1007/s12026-023-09379-z · Cited by 6
An up-to-date review of emerging biologic therapies for hypercholesterolemia
Tomlinson, B. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2442455 · Cited by 6
Gagnon, É., Gill, D., Chabot, D., Cronjé, H. T., Yuan, S., Brennan, S., Thériault, S., Burgess, S., Arsenault, B. J., & Dib, M. (2025) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.124.004933 · Cited by 8
Advances in diagnosis and potential therapeutic options for familial chylomicronemia syndrome
Benes, L. B., Brandt, E. J., & Davidson, M. H. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1419863 · Cited by 6
Verbeek, R., Oldoni, F., Surendran, R. P., Zwinderman, A. H., Khaw, K., Stroes, E. S. G., Wareham, N. J., Boekholdt, S. M., & Dallinga‐Thie, G. M. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.02.005 · Cited by 6
Life is complicated: so is apoCIII
Reyes‐Soffer, G., & Ginsberg, H. N. (2019) · Journal of Lipid Research · doi:10.1194/jlr.c119000214 · Cited by 6
Cui, H., & Du, Q. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-1592-5_8 · Cited by 6
Treatment of the metabolic syndrome by siRNA targeting apolipoprotein CIII
Recio-López, P., Valladolid‐Acebes, I., Hadwiger, P., Hoßbach, M., Krampert, M., Prata, C. A. H., Berggren, P., & Juntti‐Berggren, L. (2022) · BioFactors · doi:10.1002/biof.1885 · Cited by 6
Tryptophan probes reveal residue-specific phospholipid interactions of apolipoprotein C-III
Pfefferkorn, C. M., Walker, R. L., He, Y., Gruschus, J. M., & Lee, J. C. (2015) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2015.08.018 · Cited by 6
Zeggini, E., Gloyn, A. L., & Hansen, T. F. (2016) · Diabetologia · doi:10.1007/s00125-016-3926-3 · Cited by 6
Joshi, P. H., Miller, P. E., Martin, S. S., Jones, S. R., Massaro, J. M., D’Agostino, R. B., Kulkarni, K. R., Sponseller, C. A., & Toth, P. P. (2017) · AIDS · doi:10.1097/qad.0000000000001423 · Cited by 6
Liu, Y., & Han, B. (2021) · Transplant Immunology · doi:10.1016/j.trim.2021.101444 · Cited by 6
Leatherman, S. M., Ferguson, R. E., Hau, C., Harrington, K. M., Granowitz, C. B., Philip, S., Toth, P. P., Bhatt, D. L., & Boden, W. E. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.982815 · Cited by 6
Brænne, I., Zeng, L., Willenborg, C., Tragante, V., Kessler, T., Willer, C. J., Laakso, M., Wallentin, L. C., Franks, P. W., Salomaa, V. V., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182999 · Cited by 6
Should We Use Genetic Scores in the Determination of Treatment Strategies to Control Dyslipidemias?
Lechner, K., Kessler, T., & Schunkert, H. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01408-9 · Cited by 6
Sydhom, P., Al-Quraishi, B., Gohar, A., El-Shawaf, M., Shehata, N., Ataya, M., Sydhom, M., Awwad, N., Motawade, H., Naji, N., et al. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07798-8 · Cited by 5
“Individuals with loss-of-function mutations in APOC-III exhibit significantly reduced levels of triglycerides and remnant cholesterol, along with a nearly 40% reduction in ASCVD risk [32, 33].”
Bleich, D., Biggs, M. L., Gardin, J. M., Lyles, M. F., Siscovick, D. S., & Mukamal, K. J. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100725 · Cited by 5
Henry, D., Baugé, E., Staels, B., & Lalloyer, F. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100086 · Cited by 5
Safety, pharmacokinetics and pharmacodynamics of Plozasiran in Chinese healthy volunteers
Wang, F., You, D., Niu, X., Shi, J. G., Li, Y., Qi, L., & Li, H. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02929-9 · Cited by 5
Björnson, E., Packard, C. J., & Borén, J. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109010 · Cited by 6
New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering
Gaudet, D., Larouche, M., Raal, F. J., & Catapano, A. L. (2026) · Circulation Research · doi:10.1161/circresaha.126.327270 · Cited by 5
Labordiagnostik von Fettstoffwechselstörungen
März, W., Scharnagl, H., Kleber, M. E., Silbernagel, G., Nauck, M., Müller‐Wieland, D., & von Eckardstein, A. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1516-2511 · Cited by 5
Jeong, J., Rastogi, A., Kim, T., Henry, S. P., Hoffmaster, C. M., Kim, S. Y., Kim, W., Lee, S.-Y., Park, J., Wi, I.-S., et al. (2024) · Nucleic Acid Therapeutics · doi:10.1089/nat.2024.0057 · Cited by 5
Rehues, P., Girona, J., Guardiola, M., Ozcariz, E., Amigó, N., Rosales, R., Esteban, Y., Banús, H., Alsina, G. G., González-Lleó, A. M., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02531-5 · Cited by 6
Gagnon, É., Gill, D., Burgess, S., & Arsenault, B. J. (2025) · European Heart Journal Open · doi:10.1093/ehjopen/oeaf018 · Cited by 5
Maidman, S. D., & Rosenson, R. S. (2025) · BioDrugs · doi:10.1007/s40259-025-00731-3 · Cited by 7
Bayesian Variable Selection for Post-Analytic Interrogation of Susceptibility Loci
Chen, S., Núñez, S., Reilly, M. P., & Foulkes, A. S. (2016) · Biometrics · doi:10.1111/biom.12620 · Cited by 5
Analytic and Translational Genetics
Karczewski, K. J., & Martin, A. R. (2020) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-072018-021148 · Cited by 6
Nicholls, S. J., & Nelson, A. J. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2362644 · Cited by 6
APOC3: Triglycerides do matter
Hassan, M. S. (2014) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2014.38 · Cited by 5
APOC3 may not be a predictor of risk of ischemic vascular disease in the Chinese population
Tang, L. V., Cheng, Z., Wang, Q., Zeng, W., Liu, H., Wu, Y., Hu, B., & Hu, Y. (2014) · F1000Research · doi:10.12688/f1000research.5676.1 · Cited by 5
Volta, A., Hovingh, G. K., & Grefhorst, A. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000489 · Cited by 5
Genomic Strategies Toward Identification of Novel Therapeutic Targets
Kessler, T., & Schunkert, H. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_360 · Cited by 5
Corbin, L. J., Hughes, D. A., Chetwynd, A. J., Taylor, A. E., Southam, A. D., Jankevics, A., Weber, R. J. M., Groom, A., Dunn, W. B., & Timpson, N. J. (2020) · Metabolomics · doi:10.1007/s11306-020-01689-9 · Cited by 5
National Heart, Lung, and Blood Institute (NHLBI) Strategic Visioning
Lauer, M. S., Kiley, J. P., Mockrin, S. C., Mensah, G. A., Hoots, W. K., Patel, Y., Cook, N. L., Patterson, A. P., & Gibbons, G. H. (2015) · Circulation · doi:10.1161/circulationaha.115.015712 · Cited by 6
Li, J., Zhao, D. H., Liu, J., Wang, M., Sun, J., Liu, J., Li, Y., Deng, Q., & Qi, Y. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-052388 · Cited by 5
Genetically Engineered Hamster Models of Dyslipidemia and Atherosclerosis
Xian, X., Wang, Y., & Liu, G. E. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1924-7_26 · Cited by 6
Takashima, M., Taniguchi, K., Nagaya, M., Yamamura, S., Takamura, Y., Inatani, M., & Oki, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-45088-1 · Cited by 5
Kastelein, J. J. P. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61332-5 · Cited by 5
Crawford, D. C., RESTREPO, N. A., Diggins, K. E., Farber‐Eger, E. H., & Wells, Q. S. (2018) · BMC Medical Genomics · doi:10.1186/s12920-018-0387-1 · Cited by 5
Beyond Statins: Who and When to Prescribe?
Ganda, O. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1087-0 · Cited by 5
Insights into blood lipids from rare variant discovery
Schmidt, E. M., & Willer, C. J. (2015) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.06.008 · Cited by 5
Yes, hyperglycaemia is indeed a modifiable cardiac risk factor: so says Mendel
Bhatt, D. L. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv094 · Cited by 5
Bayesian model comparison for rare variant association studiesPreprint
Venkataraman, G. R., DeBoever, C., Tanigawa, Y., Aguirre, M., Ioannidis, A. G., Mostafavi, H., Spencer, C. C. A., Poterba, T., Bustamante, C. D., Daly, M. J., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/257162 · Cited by 5
Wall, J. D., Sathirapongsasuti, J. F., Gupta, R. K., Barik, A., Kumar, R., Rasheed, A., Radha, V., Belsare, S., Menon, R., Phalke, S., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3728138 · Cited by 5
Advancing RNA-targeted therapy for personalised prevention of coronary disease: focus on ANGPLT3
Landmesser, U., & Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa790 · Cited by 5
Emerging therapies for refractory hypercholesterolemia: a narrative review
Pawlos, A., Khoury, É., & Gaudet, D. (2024) · Future Cardiology · doi:10.1080/14796678.2024.2367860 · Cited by 4
Kouvari, M., Valenzuela‐Vallejo, L., Guatibonza-García, V., Verrastro, O., Axarloglou, E., Mylonakis, S. C., George, J., Papatheodoridis, G., Mingrone, G., & Mantzoros, C. S. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.10.007 · Cited by 4
Wei, X., Wang, M., Yu, S., Han, Z., Li, C., Zhong, Y. Q., Zhang, M., & Yang, T. (2025) · Medicine · doi:10.1097/md.0000000000041368 · Cited by 4
Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors
Mansoor, T., Nambi, V., Parikh, S. S., Misra, A., Ismayl, M., Sullivan, C., Sperling, L. S., Virani, S. S., Rifai, M. A., Koshy, S. K. G., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00748-7 · Cited by 4
Erbasan, E., Aliciaslan, M., Erendor, F., Şanlioğlu, A. D., & Şanlıoğlu, S. (2025) · Gene Therapy · doi:10.1038/s41434-025-00575-0 · Cited by 5
Qiu, Z., Wang, R.-Y., Zhang, Y., Huang, H.-B., He, R.-Y., Yan, H., Luo, P., Yang, B., Xu, Z.-F., & He, Q.-J. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01729-x · Cited by 6
Ginsberg, H. N., & Bornfeldt, K. (2026) · Circulation Research · doi:10.1161/circresaha.125.327267 · Cited by 4
An adaptive test for meta‐analysis of rare variant association studies
Yang, T., Kim, J., Wu, C., Ma, Y., Wei, P., & Pan, W. (2019) · Genetic Epidemiology · doi:10.1002/gepi.22273 · Cited by 4
Triglycerides and Atherosclerotic Cardiovascular Disease.
Puri, R., Mehta, V., Iyengar, S. S., Narasingan, S. N., Duell, P. B., Sattur, G. B., Vijayaraghavan, K., Mohan, J. C., Wangnoo, S. K., Dalal, J. J., et al. (2020) · PubMed · Cited by 4
Comparison of multiple imputation and other methods for the analysis of imputed genotypes
Auer, P. L., Wang, G. T., Li, G., DeWan, A. T., & Leal, S. M. (2023) · BMC Genomics · doi:10.1186/s12864-023-09415-0 · Cited by 4
DNA and RNA Molecules as a Foundation of Therapy Strategies for Treatment of Cardiovascular Diseases
Rakicevic, L. B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082141 · Cited by 4
The era of targeted therapy for hyperlipidemia
Чубыкина, У. В., Tyurina, A. V., & Владиславович, Е. М. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6038 · Cited by 6
Metadata
- Authors
- The TG and HDL Working Group of the Exome Sequencing Project, N. H.
- Corresponding author
- The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-03
- Volume
- 371
- Issue
- 1
- Pages
- 22-31
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4180269
- OpenAlex
- W2170009139
- Semantic Scholar
- b3c2b9d4976782980ff38a64e223209866004dcc
- Cited by
- 1,071
- References
- 66
- Citations by year
- 2026: 52 · 2025: 73 · 2024: 48 · 2023: 56 · 2022: 75 · 2021: 93 · 2020: 110 · 2019: 90 · 2018: 81 · 2017: 113 · 2016: 132 · 2015: 107 · 2014: 41
- FWCI
- 89.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion)
- Funders
- U.S. Department of Agriculture
- Massachusetts General Hospital (R01HL107816)
- University of Wisconsin-Milwaukee
- George Washington University
- University of Washington
- Donovan Family Foundation
- University of Ottawa
- Norges Teknisk-Naturvitenskapelige Universitet
- Queen Mary University of London
- Wellcome Trust
- Deutsches Zentrum für Herz-Kreislaufforschung
- Università degli Studi di Milano
- University of Texas Health Science Center at Houston
- Broad Institute
- Russell and Diana Hawkins Family Foundation
- National Institute for Health and Care Research (NF-SI-0611-10170)
- British Heart Foundation
- University of Leicester
- University of Oxford
- University of Leeds
- Fondation Leducq (T32HL007208)
- Lunds Universitet
- Hjärt-Lungfonden
- King Abdulaziz University
- Universität zu Lübeck
- Umeå Universitet
- Technische Universität München
- Università degli Studi di Verona
- Rheinische Friedrich-Wilhelms-Universität Bonn
- Novo Nordisk Fonden (NNF14OC0009819, NNF13OC0005339, NNF14OC0011049)
- Regione Emilia-Romagna
- National Institutes of Health (1rc2hl103010-01)
- School of Medicine, Stanford University
- University of North Carolina at Chapel Hill
- Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai
- Canadian Institutes of Health Research
- Medical Research Council
- Barts and The London School of Medicine and Dentistry
- Helmholtz Zentrum München
- National Institute on Aging (P30AG010129, U01AG049505)
- National Heart, Lung, and Blood Institute (HL 102923, RC2HL102925, HL-102924, K08HL114642, RC2HL102926, RC2HL102923, RC2HL-103010, HL 103010, RC2HL102924, R01HL107816, T32HL007208, R01HL109946)
- National Cancer Institute (R01CA082659)
- National Institute of Neurological Disorders and Stroke (R01NS017950)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein C-III, loss-of-function mutations, plasma triglycerides, coronary artery disease, rare variants, splice site mutation, nonsense mutation, missense mutations, genetic risk, European ancestry, African ancestry
- MeSH terms
- Coronary Disease, Genotype, Heterozygote, Humans, Liver, Mutation, Risk Factors, Triglycerides, Sequence Analysis, DNA, Black People, White People, Apolipoprotein C-III, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
